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DEVELOPMENT OF A MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS) 
VACCINE FOR GROUP B STREPTOCOCCUS 
ADRIAN MIGUEL ALONSO 
ABSTRACT 
 
Background: Group B Streptococcus (GBS) is a Gram-positive bacterium that is a 
common cause of infection in neonates and is the predominant pathogen causing 
meningitis in infants. Different vaccine formulations have been evaluated in preclinical 
and/or clinical settings, such as polysaccharide-based vaccines, protein-based, 
polysaccharide-protein conjugate vaccines, and most recently a Multiple Antigen 
Presenting System (MAPS) vaccine. MAPS is a vaccine that is being developed in the 
Malley laboratory at Boston Children’s Hospital that consists of GBS polysaccharides 
and proteins that are combined using affinity interactions.   
The overall aim of this thesis is to contribute towards the development of an 
effective MAPS vaccine by identifying high capsule-producing GBS isolates, optimizing 
conditions for polysaccharide purifications, characterizing the immune response to carrier 
protein derivatives, and creating MAPS complexes with GBS-specific protein carriers.  
 
Methods: The serotypes of 61 GBS clinical isolates were identified via multiplex PCR. 
To determine high producing strains, the supernatant polysaccharide concentrations 
(SPC) for type Ia and III were measured by type 14 pneumococcal and GBS Ia ELISAs, 
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respectively. In addition, type III isolates were grown in different conditions (shaking vs. 
static, Todd Hewitt Broth vs. Todd Hewitt Broth + 0.5% yeast extracts).  
For carrier protein production, genetically conserved alpC and rib were ligated 
onto a pet21b C terminally tagged rhizavidin (protein made by Rhizobium etli that has a 
very high affinity for biotin) vector. AlpC was purified and used to immunize rabbits. To 
determine whether the location of the terminal rhizavidin tag affected the 
immunogenicity of the proteins, we compared the serum titers of C- and N-terminally 
tagged proteins by ELISA.  Additionally, AlpC was conjugated to purified pneumococcal 
type I polysaccharide for the creation of MAPS complexes.  
 
Results: We serotyped 61 clinical GBS isolates, of which 18 were type Ia and 33 were 
type III. The type Ia isolate 21 and type III isolate 25 produced the most polysaccharide 
relative to the other isolates. The majority of the isolates for type III produced more 
capsule under shaking conditions and when grown in THY (Todd Hewitt Broth +0.5% 
yeast extracts).  
 AlpC and rib were successfully cloned into pet21b CRhiz plasmid and purified. 
To determine if the position of the rhizavadin tag affected immunogenicity, AlpC-C 
terminus was sent for immunization onto rabbits. This protein generated similar antibody 
titers than a N-terminally tagged AlpC.  
 
Discussion: The majority of isolates identified from patients were type Ia and III which 
corresponds to published data stating that Ia and III are amongst the most common 
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serotypes associated with early onset disease. Production of capsule was greatest in 
isolate 21 for the Ias and isolate 25 for the III, which may be due to enhanced expression 
of the cps operon.  
 The data for serum titers from AlpC revealed no major difference between titers 
generated by the C-and N-terminally tagged proteins. This suggests that placing the 
rhizavadin tag at the C-terminus or N-terminus for AlpC does not affect immunogenicity.  
 
Conclusion: This work presented in this thesis contributed to the development of an 
effective GBS MAPS vaccine by finding high producing strains to optimize 
polysaccharide purifications, and purifying AlpC and immunizing with this carrier 
protein.  
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INTRODUCTION 
 
Epidemiology and risk factors for infection 
Streptococcus agalactiae, which is also termed Group B Streptococcus (GBS), is 
a Gram-positive commensal pathogen sub-divided into ten different serotypes (Ia, Ib, II-
IX). GBS commonly colonizes the urogenital and gastrointestinal tracts of humans. It is 
estimated that 20-30% of all expecting mothers are colonized with GBS. From this group, 
half of their infants will be colonized and 1% will develop GBS-related disease 
(Nuccitelli, et al., 2015).  
International population-based surveillance checks have been performed to 
determine the worldwide burden of GBS. These analyses estimated an incidence of GBS 
infection of 0.53 per 1000 live births. Incidence of disease is greatest in Africa 
(1.21/1000), then the Americas (0.67/1000) and Europe (0.57/1000) while Southeast Asia 
has the lowest rate (0.02/1000) (Nuccitelli, et al., 2015).  
It has been estimated that of the 140 million births in 2015, 21.3 million newborns 
were exposed to maternal GBS. From these 21.3 million, an estimated 319,000 cases of 
GBS disease occurred, leading to 90,000 neonatal deaths. Of the newborns that survived 
despite GBS infection, 10,000 were estimated to suffer from neurodevelopmental 
impairment, mainly as a consequence of meningitis (Seale, et al., 2017).  
Neonatal infection syndromes are categorized into two disease types: early onset 
disease (EOD) and late onset disease (LOD). Early onset disease, which comprises for 
60-70% of GBS newborn illness, occurs within the first few days (<7) post-partum. In 
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EOD the infant acquires GBS through maternal bloodstream or urogenital tract prior to, 
during or shortly after delivery. This type of infection can proceed rapidly, and in 98% of 
cases infection results in pneumonia or sepsis. The GBS serotypes most commonly 
associated with EOD are Ia and III (Gibbs, et al., 2004; Puopolo, et al., 2005; Simonsen, 
et al., 2014; Edmond, et al., 2012).  
In contrast, LOD occurs in infants older than 1 week. The pathogenesis of LOD 
has not been definitively established, but it appears that the infant may become GBS-
colonized during delivery, and develops disease after the recently acquired organism 
invades the bloodstream. This type of infection is represented by meningitis in 50% of 
cases (Heath and Schuchat, 2007). Around 50% of newborns who survive LOD suffer 
defects, such as mental retardation and hearing loss. The GBS serotype that is most 
associated with this type of infection is type III (Schuchat, 1999; Heath and Schuchat, 
2007). 
 According to the CDC, some pregnant mothers have a significantly greater risk of 
having a baby who develops EOD. Maternal risk factors include the detection of GBS in 
maternal urine, a positive test for vaginal or rectal GBS colonization when 35-37 weeks 
pregnant, an early delivery, development of a fever while giving birth, a significant 
amount of a time gap between ruptured membranes and delivery, and having a previous 
child who developed EOD (CDC, 2016).  
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Capsular polysaccharides of GBS 
 Because of the severity of GBS and the global health burden due to this organism, 
GBS has been extensively studied in the past decades. GBS strains are distinguished from 
other streptococci in that they have a common epitope termed the Lancefield Group B 
polysaccharide. Between each GBS strain, serotypes are differentiated by ten different 
capsular polysaccharides (CPS) (Ia, Ib, II-IX). Although each capsular polysaccharide is 
unique, all have a terminal N-acetylneuraminic acid (sialic acid) side chain (Nuccitelli, et 
al., 2015; Wessels, 1997). Of these serotypes, Ia, Ib, II, III and V contribute towards most 
of infections (Heath, 2016).  
Much research has been conducted on type Ia and III serotypes. The enzymes 
required for type Ia and III CPS production are assembled via the cps operon. The 
backbone of these polysaccharide consist of repeating [b-D-N-acetylglucosamine-(1,3)- 
b-D-galactose (1,4)- b-D-glucose-(1, )n tri-saccharide units. The repeating units contain a 
side chain of the disaccharide a-D-N-acetylneuraminic acid- n(2,3)- b-D-galactose (1, 4) 
linked to galactose to the backbone N-acetyl-glucosamine (Chaffin, et al., 2000).  
Ia is a polymer of b-1,4 linked lactose where a tri-saccharide side chain of a-D-N-
acetylneuraminic acid-(2, 3)- b-D-galactose (1, 4)- b-D-N-acetylglucosamine is attached 
to all units of galactose via a b-D-N-acetylglucosaminyl-(1, 3) linkage (Chaffin et al, 
2000). Thus, the polysaccharide repeating units (PRUs) are almost identical with the 
exception of an extra sugar on the type III polysaccharide and a difference in glyosidic 
bond linkages (Chaffin, et al., 2000). 
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Pathogenesis of infection 
Clearance of GBS from the blood and deep tissues relies on ingestion by 
phagocytes. Phagocytosis occurs when GBS strains are opsonized by serum complement, 
which is boosted by polysaccharide-specific antibodies. When no specific antibodies are 
present, bacterial-complement activation is believed to proceed through the alternative 
complement pathway (Wessels, 1997). However, it has been shown that highly 
encapsulated type III GBS strains do not activate the alternative pathway, allowing them 
to elude the immune system. It has also been shown that the amount of C3b deposed on 
bacterial surfaces is inversely correlated to the amount of capsular polysaccharide 
(Marques, et al., 1992). Additionally, data suggests that the GBS type III sialic acid 
polysaccharide reduces murine bactericidal capacity and cytokine levels and increases 
bacterial virulence. In the absence of sialic acid, bacteria were significantly less able to 
infect mice bladders compared to mice that had sialic acid-containing polysaccharides 
(Kline, et al., 2011).  
 
History of GBS prevention and vaccination  
To prevent GBS infections in newborns, in 1996 the CDC recommended that all 
pregnant women undergo a vaginal and rectal screen at 35-37 weeks’ gestation to detect 
the presence of GBS and the administration of intrapartum antimicrobial prophylaxis 
(IAP) to colonized pregnant women. Following this recommendation, the incidence of 
EOD declined from 0.47/1000 births to 0.34/1000 births in the US. This method 
continues to be the most common approach for GBS prevention. Although successful in 
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reducing the amount of cases, IAP method suffers from some limitations, including risk 
of allergic reactions to the antibiotics, false negative test results, and delays in diagnosis.  
Importantly, no reduction in the incidence of LOD has been observed, presumably 
because the pathogenesis of this disease differs from EOD (Nuccitelli, et al., 2015).  
Vaccines represent a more attractive method to prevent GBS disease. A vaccine 
administered to a pregnant woman would stimulate antibody production that can cross the 
placenta and passively immunize the child (Palmeira, et al., 2012). The first prototype 
vaccine against GBS was created by Rebecca Lancefield in the 1930s, who showed that 
mice were protected from GBS infections when immunized with CPS-specific rabbit 
serum (Lancefield and Hare, 1935). In epidemiologic studies, Baker and Kasper also 
showed that maternal IgG specific for GBS capsule was associated with a reduced risk of 
invasive GBS disease in infants (Baker and Kasper, 1976). In the 1980s, unconjugated 
serotype-specific polysaccharides were used in phase I clinical trials. Although proving 
safe for usage, these vaccines lacked the ability to generate an effective immune response 
in all patients. Additionally, polysaccharide-based vaccines activate B cells to secrete 
antibodies in a T-cell-independent manner, lacking the ability to generate a memory 
immune response (Baker and Kasper, 1985; Baker, et al., 1988).  
 In the early 20th century, research showed that the immunogenicity of 
polysaccharides could be increased by conjugating them to protein carriers. The 
conjugation of polysaccharides to proteins presents the polysaccharide epitopes to T cells, 
which then stimulate B cells to proliferate (Avci and Kasper, 2010). For example, for 
pneumococcal vaccines, three major vaccines are currently used to date, PPSV 23 
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(polysaccharide only), and PCV7/PCV13 (conjugate vaccines). For PPSV 23, the rate of 
invasive pneumococcal disease decreased after vaccine implementation, but this vaccine 
failed to elicit an immune response in children <2 years of age, likely because it does not 
establish T-cell-dependent immunity (Daniels, 2016).  
To develop immune responses in children under the age of 2, conjugate vaccines 
using pneumococcal polysaccharide conjugated to diphtheria toxin were constructed 
(PCV7). This vaccine greatly reduced the rate of infections in children, and 
hospitalizations due to pneumococcal infections decreased significantly. PCV13 offered 
increased coverage compared to PCV7, and OPA responses for 8 serotypes were 
significantly greater than PPSV23. Studies as such depict the importance of generating a 
conjugate vaccine due to their ability to confer greater immunity across a greater age 
range (Daniels, 2016; Jackson, 2013).  
Currently, there are five common protein carriers that are in licensed vaccines: 
diphtheria toxin, tetanus toxoid (TT), meningococcal outer membrane protein complex 
(OMPC), diphtheria toxoid, and H. influenza protein D (Pichichero, 2013).  
 For GBS, conjugate vaccines made with GBS CPS (Ia, Ib, II-VIII) that have been 
conjugated to the protein carrier tetanus toxoid (TT) showed a greater immune response 
than the uncoupled CPS in animals (Wessels, et al., 1990; Paoletti, et al., 1992, 1994, 
1992; Paoletti and Kasper, 2002; Paoletti and Madoff, 2002). Phase I trials using CPS 
coupled to TT showed that after immunization of pregnant women, IgG titers were 
greater than those in women who received only unconjugated CPS (Kasper, et al., 1996). 
Monovalent conjugate vaccines towards a variety of GBS serotypes have been created 
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and tested in phase I and II trials on healthy women, and each vaccine showed excellent 
immunogenicity (Nuccitelli, et al., 2015). Although type-specific conjugate vaccines 
proved to be immunogenic, the immunity was serotype-specific. In search for a better 
vaccine, scientists studied common proteins associated with the organism of interest in 
order to create a vaccine that would confer broad range immunity, such as the beta C 
protein in GBS (Madoff, et al., 1992).  
Several genetically conserved proteins have been evaluated.  In particular, one 
study showed that 90% of clinically infectious strains express either Alpha or Rib surface 
proteins. It has also previously been shown that vaccination of mice with purified Rib and 
Alpha proteins conferred protection to several GBS serotypes (Larsson, et al., 1996). 
Additionally, a clinical study examining neonatal sera against Rib and Alpha proteins 
showed a correlation between low level of antibodies against these surface proteins and 
increased risk of GBS infection by Rib-expressing strains (Larsson, et al., 2006). 
Therefore, some have proposed that a conjugate vaccine of GBS CPS with Alpha and Rib 
may be an attractive solution, to generate antibodies to the CPS and proteins (Paoletti, et 
al., 2002). The proteins of interest of this thesis are Rib and Alpha like protein (AlpC), a 
protein that cross reacts with both Rib and Alpha proteins (Areschoug, et al., 1999).  
More recently, Zhang et al created an acellular, Multiple Antigen-Presenting 
System (MAPS) vaccine, with the ability to immunologically mimic a whole cell vaccine, 
without the potential risks associated with a cellular construct. This complex uses 
polysaccharides and proteins as immunogens, where the antigen components are 
reassembled into a macromolecular complex (Zhang, et al., 2013). 
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MAPS is constructed using an affinity-based coupling approach. A biotin binding 
protein named rhizavidin (rhavi), a protein made by Rhizobium etli, is genetically fused 
to a protein antigen of interest, expressed recombinantly in E. coli and purified. In 
parallel, the antigenic polysaccharide is biotinylated. These antigens are then incubated 
and mixed, and attach to one another via a strong affinity linkage of biotin and rhavi 
(Helppolainen, et al., 2007; Zhang, et al., 2013). 
It has been shown that immunization of mice with MAPS elicits a greater IgG 
response specific for the polysaccharide, and greater T cell responses as compared to un-
complexed polysaccharides and proteins. Importantly, MAPS is able to generate B-cell 
responses to the polysaccharide and the proteins as well as Th1/Th17 responses to the 
proteins, a promising approach for vaccine development (Zhang, et al., 2013).  
 
Hypothesis  
The goal of this thesis is to develop a prototype MAPS vaccine comprised of 
AlpC and Rib coupled to GBS capsular polysaccharide. The overarching hypothesis is 
that a GBS MAPS-based vaccine composed of GBS polysaccharide complexed with 
AlpC and Rib will confer serotype-specific immunity as traditional conjugate vaccines, 
but also provide heterologous protection towards multiple GBS serotypes via immunity 
to conserved proteins. 
 
Specific aims 
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1. To identify the serotypes of 64 clinical isolates obtained from the microbiology 
laboratory of a large pediatric hospital. 
2. To identify type III isolates that are high producers of capsular polysaccharide. 
3. To develop an effective inhibition ELISA for quantification of type Ia CPS. 
4. To analyze capsule production under different growth conditions.  
5. To purify the type Ia capsular polysaccharide for creation of MAPS and future 
vaccination studies. 
6. To clone and express two conserved immunogenic proteins, AlpC and Rib, for 
creation of MAPS complexes. 
7. To compare the antibodies titers generated in response to C- and N-terminally 
tagged AlpC and Rib.  
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METHODS 
 
Bacterial strains and growth conditions 
Anonymized clinical GBS isolates from routine patient screens were obtained 
from the clinical microbiology laboratory at Boston’s Children’s Hospital (BCH). The 
M781, type III strain, was a kind gift from Dr. Michael Wessels, also at BCH. A type IV 
GBS (C28) strain was obtained from Dr. Marc Lipsitch’s laboratory at Harvard School of 
Public Health.  GBS isolates were streaked onto blood agar plates and routinely cultured 
in Todd-Hewitt Broth supplemented with 0.5% yeast extracts (THY) where appropriate at 
37°C with agitation at 180 rpm.  
Recombinant E. coli strains were streaked onto LB agar with 100ug/ml ampicillin 
(LBA) where appropriate and cultured in LBA broth overnight at 37C. 
 
Transformation protocol for DH5a-E cells 
DH5a-E. coli competent cells were thawed on ice for 10 minutes. Two µL of 
ligation products were added to tubes containing 25 µL of the bacteria. The mixture was 
placed back on ice for 30 minutes, followed by a heat shock at 42°C for exactly 30 
seconds, then placed back on ice for 5 minutes. Five hundred µL of SOC were added to 
each and placed at 37°C for 1 hour at 250 RPM (NEB protocol).  
 
Identifying the serotypes of 64 clinical isolates using PCR 
Genomic DNA extraction of 64 clinical isolates, C28 and M781 
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Overnight cultures were centrifuged at 2500 x g for 10 mins at 4°C and pellets 
were re-suspended in 1 mL phosphate buffered saline (PBS). Twenty µL of 10,000 U/mL 
of mutanolysin and 100mg/mL lysozyme were added to each sample and incubated at 
37°C for 10 min.  
Samples were spun at 200 x g for 10 minutes and pellets were re-suspended in 
500 µL of SET buffer (75 mM NaCl, 35 mM EDTA, 20 mM Tris, pH 7.5) supplemented 
with 50 µL of 10% SDS and 5 µL of 50 mg/mL proteinase K. Samples were incubated at 
55°C for 2 hours. Five M NaCl and chloroform were added to all samples and 
centrifuged at 16,000 x g for 15 mins. Aqueous layers were collected, and 1 volume of 
isopropanol was added to each sample. All samples were then inverted gently to 
precipitate the DNA and centrifuged. Pellets were rinsed with 70% ethanol. Ethanol was 
aspirated and pellets were left to air-dry and dissolved in dH2O (Pospiech, et al., 1995).  
Two µL of genomic DNA were used for PCR reactions. Two types of primer 
master mixes were made, one containing primers for serotypes Ia-IV, and the other 
containing V-VIII and an internal positive control primer that targeted the dltS gene 
(Table 1) (Poyart, et al., 2007).  
Primer Sequence (5’-3’) Amplicon 
size(s) (bp) 
Ia-F GGTCAGACTGGATTAATGGTATGC 521 and 1826 
Ia-R GTAGAAATAGCCTATATACGTTGAATGC  
Ib-F TAAACGAGAATGGAATATCACAAACC 770 
Ib-R GAATTAACTTCAATCCCTAAACAATATCG  
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II-F GCTTCAGTAAGTATTGTAAGACGATAG 397 
II-R TTCTCTAGGAAATCAAATAATTCTATAGGG  
III-F TCCGTACTACTACAACAGACTCATCC 1826 
III-R AGTAACCGTCCATACATTCTATAAGC  
IV-F GGTGGTAATCCTAAGAGTGAACTGT 578 
IV-R CCTCCCCAATTTCGTCCATAATGGT  
V-F GAGGCCAATCAGTTGCACGTAA 701 
V-R AACCTTCTCCTTCACACTAATCCT  
VI-F GGACTTGAGATGGCAGAAGGTGAA 487 
V-R AACCTTCTCCTTCACACTAATCCT  
 
VII-F CCTGGAGAGAACAATGTCCAGAT 371 
VII-R GCTGGTCGTGATTTCTACACA  
VIII-F AGGTCAACCACTATATAGCGA 282 
VIII-R TCTTCAAATTCCGCTGACTT  
dltS-F AGGAATACCAGGCGATGAACCGAT 952 
dltS-R TGCTCTAATTCTCCCCTTATGGC  
Alpc F ATGGCT 500 
AlpC R GAGCTC  
Rib F CATATG 500 
Rib R GAGCTC     
Table 1: List of primers from Poyart, et al., 2007 
The polymerase used for the PCR reaction was Gotaq. PCR was performed using 
Gotaq Green Mastermix (Promega) with the following cycling conditions: denaturation 
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stage (95°C for 2 minutes), annealing stage (95°C for 30 seconds, 50°C for 30 seconds, 
72°C for 2 minutes), and an extension stage (72°C for 5 minutes). PCR products were 
visualized on a 0.8% agarose gel using Sybersafe gel stain from Thermo Fischer, and 
band sizes were compared to those published to identify the serotypes (Poyert et al).  
 
Purification of type Ia isolate 21 capsular polysaccharide 
Isolate 21 was inoculated 1:100 into 2L of 900 mL 0.5 THB with 100 mL of 10 x 
feed solution (720 mM sodium phosphate dibasic, 170 mM sodium phosphate 
monobasic, 10% glucose), and grown overnight. Culture was then centrifuged at 10,000 x 
g and supernatant was filtered. pH of supernatants was adjusted to roughly 7 with NaOH 
and concentrated to 50 mL by TFF using a 30kDa cut off cassette. Remaining supernatant 
was dialyzed overnight with dH20. 
 The dialyzed supernatant was adjusted to 30% ethanol and incubated on ice for 
15 minutes and spun at 10,000 x g for 20 minutes. The capsule polysaccharide (CPS) was 
then adjusted to 80% ethanol and incubated on ice for 15 minutes and spun. The pellets 
were re-suspended in 2 mL dH20. Solution was than incubated with 1:5000 dilution of 10 
kU/mL pronase for 2 hours at 55°C. Pronase was heat inactivated at 100°C for 15 
minutes and placed on ice. Solutions were centrifuged at 16,000 x g for 10 minutes and 
passed through a 0.2 µm syringe filter. This crude CPS was loaded onto the HPLC 
column for purification, followed by anion exchange using a 5 mL DEAE column. NaCl 
concentration gradient range was from 50 mM-250 mM over 10 column volumes. 
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Fractions were eluted at 2.5 mL per fraction. After HPLC, an anion-exchange 
chromatography was performed.  
 
Anthrone assay for type Ia capsular polysaccharide concentration 
Anthrone assay on HPLC purified isolate 26: The anthrone assay standard curve 
ranged from 1000 µg/mL of type 14 pneumococcal polysaccharide solution to 7.81 
µg/mL. Because of the similarities of the type 14 pneumococcal polysaccharide to the 
GBS Ia polysaccharide, this standard was deemed appropriate to use for accurate 
measurements. Twenty µL of the overnight lyophilized sample was loaded. One hundred 
µL of anthrone reagent was loaded into each well. Plate was then sealed heated with a 
100°C hot block for 20 minutes and was read at 562 nm. Polysaccharide was diluted in 
10 mL of dH2O to 1µg/mL and Maxisorp plates were coated with the solution.    
 
BCA assay protocol for dot and western blots to determine protein concentration 
The concentration of protein was determined by bicinchoninic acid assay (BCA) 
using the Pierce protein assay kit (ThermoFisher) according to the manufacturer’s 
instructions. Ten µL of each sample or standard was placed onto a 96 well plate. Blank 
wells consisted of 10 µL of PBS. One hundred µL of a 50:1 ratio of reagent A (sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium 
hydroxide) and reagent B (4% of cupric acid) was added to every well. The solutions were 
mixed for 30 seconds, and then placed in a static 37°C incubator for 30 minutes. Wells 
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were read at an O.D. at 560 nm and protein concentrations were determined by comparison 
to a BSA (bovine serum) standard (2000 -25 ug/ml).     
 
Dot blot for cross reactivity of type Ia antisera and HPLC fractions 
Cross reactivity: A BCA assay with C28, M781, a type V, II, Ib and three type Ias 
was performed. Protein concentrations were diluted down to 25 µg/mL. To perform a dot 
blot, PDVF membranes were charged in 100% methanol and de-ionized water for 20 
seconds, respectively. Ten µL of each diluted isolate was loaded onto three separate 
PDVF membranes in triplicates. Membranes were blocked and incubated with a 1:5000 
dilution of primary antibody, type Ia antisera, for 2 hr at RT with gentle agitation. 
Membranes were washed three times in fifteen minute intervals in PBS + 0.5% 
tween buffer and the membranes were incubated with donkey anti rabbit IgG at a 
1;10,000 dilution. Membranes were developed using SuperSignal West Pico 
Chemiluminescent Substrate (supplier) for an image at a 2-minute exposure in a dark 
room.  
Isolate 26 fractions: Four µL of fractionated extracts from HPLC purification 
were plotted onto two separate PDVF membrane. This was left to incubate in blocking 
buffer at 37°C for 5 hours. Primary antibody for membranes were anti-type IV sera and 
anti-type Ia-TT sera. 
 
	
 
16 
 
Western blot for AlpC and Rib cross reactivity 
AlpC and Rib reactivity: To test the cross reactivity between AlpC and Rib using 
different antisera, a western blot was performed. To do so, the concentrations of tagged 
rhizavidin AlpC and Rib were measured, and protein levels were normalized to 200 
µg/mL in PBS.  
4 x LDS and 1M DTT were added to aliquots of AlpC and Rib and heated to 70°C 
for five minutes. One mg/mL of AlpC and Rib were added into a protein gel in triplicates. 
The gel was set to 200 Volts for 35 minutes. PDVF membrane was charged and the gel 
was transferred onto the membrane at 30 volts for 1 hour. Four separate membranes were 
left to incubate with different types of antiserums at a 1:5,000 dilution, type Ia, IV, and 
V, and Ib for two hours. Membranes were then washed three times in fifteen minute 
intervals. Peroxidase conjugated donkey-anti rabbit IgG was added for 1 hour, at a 
1:10,000 dilution and washed. Images were developed at a two-minute exposure.   
 
Development of a type Ia ELISA for polysaccharide quantification 
Because there was initially no available type Ia polysaccharide for coating, the 
process to coat Maxisorp plates for the Ia ELISA was more involved. An 
immunodiffusion assay was performed on several Ia isolates to detect antigen (Ia 
polysaccharide) and antibody binding. To do so, a solution made of 2% noble agar in 
PBSN (PBS containing 0.05 % NaN3) was combined with polyethylene glycol solution 
(PEG) (4% PEG 8000 in PBSN, pre-warmed to 52°C) at a 1:1 ratio. This solution was 
poured onto gel loading plates and left to solidify. A 10ml pipette was used to puncture 
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holes to accommodate antigens and antisera. Ten µL of undiluted antisera, type Ia, was 
placed in the center hole, and 10 µL of antigen (type Ia polysaccharide) from isolates 21, 
26 and 20, were placed in the surrounding wells. Gel was left in a humidified chamber 
overnight, stained for 1 hour, and placed in de-staining solution made of 40% methanol, 
10% acetic acid, and 50% deionized H2O (Hornebeck, 2001).  
Overnight cultures of isolate 26 were used to inoculate 1L of di-filtered THY 
broth that was run through a 30,000 kD molecular weight tangential flow filtration. 
Supernatants of these cultures were collected.  
To optimize concentration readings and reduce potential cross reactivity with 
GBS type Ia proteins, we treated supernatants with 10 ku/mL of pronase at a 1:10,000 
dilution and left at 37°C for 3 hours. The treated broth was supplemented with 20mM 
Tris-HCL and 0.5M NaOH and incubated overnight at 37°C. Treated supernatant was 
then concentrated down using a 30,000 kD MW cutoff filter again until it reached a final 
volume of 50 mL. The remaining supernatant was washed with 500 mL of 1x PBS, 
followed by 500 mL of 10x PBS and concentrated back down to 50 mL. Five hundred 
mL of de-ionized water was then added twice and left to concentrate down to 50 mL. The 
remaining supernatant was lyophilized over 72 hours.  
One mL of crude type Ia capsule from isolate 26 was heated to 100°C for 15 
minutes to deactivate any remaining pronase. Sample was then cooled on ice for 10 
minutes, and spun at max speed for 10 minutes. To prepare the size-exclusion HPLC 
column, the column was washed and equilibrated with 10 mM Tris pH=7.5 + 50 mM 
NaCl. Column used was Superdex 200 10/300 GL.   
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 Fractions from the dot blot that gave strong reactivity with the type Ia antisera 
(fractions A7-B14) were pulled together and injected into a 20,000 MW cutoff filter for 
dialysis in 1L of water for five hours. The sample was then left to lyophilize overnight. 
The lyophilized sample was re-suspended in 200 µL of H2O and an anthrone assay was 
performed. This solution was used to coat the second type Ia plate.  
 
Type Ia and III polysaccharide production measurements via inhibition ELISA 
 Capsular production of all GBS type Ia and III strains were measured by using a 
type Ia and pneumococcal type 14 inhibition ELISAs, respectively. Pneumococcal 
polysaccharide type 14 differs from GBS type III polysaccharide only by the absence of a 
terminal sialic acid on the pneumococcal polysaccharide, and it has been shown that these 
polysaccharides cross react immunologically (Guttormsen, et al., 2001). Using 
pneumococcal type 14 polysaccharide can therefore be used as a standard to measure GBS 
type III polysaccharide concentrations. Maxisorp ELISA plates were coated with 100 µL 
per well of 1 µg/mL type 14 pneumococcal capsule and GBS type Ia capsule (from crude 
isolate 26 capsule) for five hours at 37°C. Plates were blocked for 1 hour with blocking 
buffer at RT (1 % skim milk powder and 0.5 % tween buffer).  
The SPC for GBS type Ia and III isolates were diluted three fold. Type Ia and III 
antisera were added to all wells at a 1:5,000 dilution and left to incubate for 1 hour. All 
wells were transferred to the type Ia and type 14 plates, respectively, and left to incubate 
for 2 hours. The plates were then washed three times in 0.5% tween buffer. Peroxidase 
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conjugated donkey anti-rabbit IgG was added to all wells at a 1:10,000 dilution and left to 
incubate for 1 hour, then the plates were washed.     
Plates were developed using tetramethylbenzidine and 1M HCl as the stopping 
reagent and wells were read at an O.D. of 600 nm. Polysaccharide concentrations for the 
type III ELISA was determined by comparison to a type 14 standard (1000 -15 ug/ml). 
Type Ia isolates were measured using a Ia polysaccharide standard, which ranged from 
500 µg/mL to 7.813 µg/mL.   
For the type Ia isolate 21 HPLC and SEC purification, DEAE and SEC 
chromatograms were obtained via type Ia inhibition ELISAs on fractions. In this case, 
starting dilutions were at 1:100.  
 
Strain selection and optimization of growth conditions for type III GBS 
GBS isolates 25, 32, 36 and 59 were selected from the type III strains and SPC 
concentrations were compared to those of M781 under different growth conditions (THY 
vs. THB-no yeast extracts and shaking vs. static growth). Polysaccharide concentrations of 
bacterial pellets were also quantified. To do so, isolates M781 and 25 were spun down and 
pellets were washed in sterile PBS. PBS was discarded after centrifugation and re-
suspended again in PBS. This was used to quantify the amount of capsule in the bacterial 
pellet.  
 Additionally, polysaccharide concentrations of M781 and 25 were measured in a 
time-dependent manner for 10 hours. Starter cultures were used to inoculate new cultures 
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1:100. Three hundred µL of each were collected for SPC measurements. Ten-fold serial 
dilutions were performed on each culture and plated onto blood agar.  
A SPC/CFU assay was performed by serially diluting isolates ten-fold and plating 
them onto blood agar plates. SPCs were then measured. Concentrations were then 
compared to their respective CFUs.  
Similarly, protein/CFU measurements were performed. Protein concentrations 
were determined by BCA, and plotted against their respective CFUs.  
 
Biofilm assay 
 Type III GBS strains grown overnight were seeded at 1:100 dilutions of THY + 
1% glucose into tissue culture treated plates coated with PBS + 2% fetal bovine serum 
(FBS). Strains were left to grow for 48 hours in the plates at 37°C. Media was discarded 
including any unattached bacteria. Plates were rinsed with dH2O twice and wells were 
left to air dry for 15 minutes. Plates were fixed using 95% ethanol for 30 minutes, and 
then rinsed. Bacteria that stuck to the wells were stained with crystal violet for thirty 
minutes, and plate was rinsed. The dye that was bound was released from the bacteria 
using 30% glacial acetic acid. The formation of biofilm was measured by examining the 
absorbance of the solution at 540 nm. Results were then compared to capsular 
concentrations (Ren Ho, et al., 2012). 
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Plasmid construction with AlpC/Rib  
Plasmid pET-21b containing a C-terminal rhizavidin tag was purified from E. coli 
using QIAquick plasmid purification kit. alpC and rib were amplified from commercial 
preparations of pUC19 using Gotaq with alpC- and rib-specific primers (see Table 1).  
The pet-21b plasmid, alpC, and rib were digested with Sac1 and Nde1 restriction 
enzymes for 5 hours at 37°C. Digests were run on a gel and PCR purified. The plasmid 
and inserts were ligated overnight at 16°C or for 2 hrs at room temperature at a 1:1 insert 
to plasmid ratio.  
Re-ligated plasmids were transformed into DH5a-E.coli competent cells.  Sixteen 
isolates from each transformation were re-suspended in 10 µL of water. Genomic DNA 
of the isolates was extracted by heat shock at 100°C for 10 minutes. A mixture of Go-taq 
polymerase and 1:10 diluted T7 primers were added to make the final reaction volume 25 
µL. Expected band sizes were roughly 1kb. Ligation was seen on colony 2 of alpC and 
colonies 5, 9 and 12 for rib. Colonies were grown overnight and plasmid was extracted.  
 Final confirmation for the ligated product was via sequencing data. Published 
alpC sequence data was aligned with sequence data (protein sequence) from the ligated 
product.  
 
Purification of AlpC  
PET-21 alpC was transformed into T7 shuffle cells. Transformations were 
inoculated 1:100 into 3L of LBA broth and grown to an O.D. of about 0.6. Cultures were 
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induced with 0.5 mM IPTG overnight at 16°C. Cultures were spun and pellets re-
suspended in 15 mL of lysate buffer (20 mM Tris/500 mM NaCl pH=8). Sixty-seven 
µL/L of protease inhibitor, 67 µL/L of 1M MgCl2 and 3 µL/L DNAase were added to the 
mixture. The cells were lysed three times for 30 seconds. The sonicated cells were then 
centrifuged at 13,000 rpm for 30 minutes.   
The nickel-NTA column was prepared by adding 500 µL of resin to the column. 
Column was washed with water and lysis buffer. The supernatant of the sonicated cells 
was mixed with the washed resin, and left on a rotor at 4°C for two hours. This solution 
was loaded twice onto the column. Column was washed with lyses buffer, followed by 
wash buffer (lysis buffer with 20mM Imidazole pH=8). Elution buffer was used to elute 
the protein (lysis buffer with 300 mM imidazole pH 8). Four fractions were collected and 
examined on an SDS gel.  
Sample fractions 1 and 2 were pulled and injected into an HPLC column for 
purification. The buffer used to equilibrate the column was 10 mM tris pH=7.5 + 150 
mM NaCl. A BCA assay was performed on HPLC fractions B12-B4. Fractions that gave 
the highest protein concentrations were pooled. Final concentration of AlpC was 425 
µg/mL.  
 
AlpC immunization studies 
 The AlpC protein was sent to Cocalico Biologicals for immunization of rabbits 
using Freund’s complete adjuvant.  Serum was collected pre- and post- immunizations. 
To quantify the titers, plates were coated with untagged (no rhizavadin) AlpC for three 
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hours. Titers had an initial dilution 1:4,000 followed by a three-fold serial dilution onto 
the plates. A standard using type IV antiserum, previously shown to have a high degree 
of cross reactivity with AlpC and Rib, was used starting at a 1:150 dilution followed by a 
three-fold dilution. 
 
Biotinylation of pneumococcal type 1 polysaccharide for MAPS 
To biotinylate type I pneumococcal polysaccharide, 0.5 mg of the PS was mixed 
with 200 µL of saline to a final concentration of 2.5 mg/mL. Three µL of CDAP (1-
cyano-4-dimethylaminopyridinium tetrafluoroborate, made in acetonitrile) was added 
into the sample solution and vortexed for 30 seconds. Six µL of Tris buffer-acetic acid-
EDTA (TAE) (10 µL + 340 µL H2O) was added and vortexed and incubated for 2 
minutes. Following this, 0.25 mg of amine-PEG3-Biotin was added and left incubating 
with rotation for 2 hours at room temperature. Solution was diluted to a final 
concentration of 50 mM and incubated with end over rotation for 30 minutes. Sample 
was dialyzed on a 20,000 MW cutoff filter in 1L of PBS (3X). The biotin concentration 
was determined using the Pierce Biotin Quantitation Kit according to the manufacturer’s 
instructions (Zhang, et al., 2013). 
For MAPS formation, different ratios of polysaccharide and AlpC were left 
incubating together over night. Ratios of polysaccharide to AlpC were 1:1, 1:3, 1:5, 1:9. 
Intact and boiled samples were viewed via an SDS gel.  
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Statistics 
 Statistics were performed using Prism (version 5.0 Graph pad software). 
Significance was determined using one or two-way ANOVA, with p<0.05 considered 
significant.  
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RESULTS 
GBS isolate obtained from patients were typed using multiplex PCR with primers 
specific for GBS Ia-IV (figure 1). Band sizes were compared to expected band sizes as 
published. Isolate serotypes were identified and serotype distribution is shown in figure 2. 
Isolate 3, 5, 13 and 31 could not be typed by these methods and may represent un-
encapsulated strains.  
 
 
 
Figure 1: Molecular Typing of Clinical GBS Isolates The DNA of 64 Group B 
Streptococcus clinical isolates was extracted using the Genomic DNA Extraction protocol 
(as outlined in the methods section). The serotypes of 61 from the 64 isolates were 
identified using PCR. The number above the lane indicates the isolate used. Expected 
band sizes (bp) for the serotypes are as followed: type Ia (521 and 1826), type Ib (770), 
type II (397), type III (1826), type IV (578). The marker is measured in kilobases.  
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Figure 2 Distribution of serotypes in clinical isolates of the 61 identifiable isolates. 
Majority were type III followed by type Ia.  
 
After identification of the isolates, the type III GBS isolates were screened to 
prospectively identify potential high capsule producers based off of SPC measurements 
(figure 3). Isolates 25, 32, 36 and 59 produced notably more SPC than M781 and were 
selected for further study.  
Distribution	of	serotypes
Type	Ia Type	Ib Type	II Type	III Type	IV Type	V
54.1%
8.2% 2%
30%
2%3.2%
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Figure 3: Quantification of capsular PS production by the clinical GBS isolates. 
 
Isolates 25 and 32 produced significantly more polysaccharide, with a four-fold 
and two-fold increase compared to M781, respectively (figure 4A).  A series of 
experiments followed for these isolates which looked at growth under different 
conditions (THB-THY, static vs shaking) (figure 4B-C) and a 10-hour kinetic experiment 
(figure 4D). The majority of the isolates produced more SPC growing in THY than THB, 
with the exception of M781 and 59, which did not reach significant difference. All 
isolates released significantly more polysaccharide into the supernatant under shaking 
conditions except for isolate 59. For the longitudinal study, no difference in 
polysaccharide concentration was seen, but M781 reached a higher CFU over the course 
of 10 hours.  
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Figure 4(A-D): Evaluation of CPS production in different experimental conditions.   
 
The goal of the next set of experiments was to determine if isolate 25 was 
inherently producing more polysaccharide/CFU (figure 5A) and to examine if bacterial 
chaining caused hyperinflation of isolate SPC measurements (figure 5B).  If chaining was 
affecting measurements, then protein concentrations for certain isolate samples would be 
significantly different from each other. The results showed that isolate 25 had a 
significantly greater capsular concentration/CFU than M781, while there was no 
significant difference in protein/CFU, meaning that bacterial chaining was most likely not 
influencing SPC measurements.  
C 
B A 
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Additionally, we wanted to determine whether or not isolate 25 released more 
polysaccharide into the supernatant than M781, if it had more cell wall associated 
polysaccharide, or both.  To do this, we took the ratio of CPS concentrations vs. cell-
associated polysaccharides. The results depicted that isolate 25 released slightly more 
polysaccharide into the supernatant than M781 (figure 5C). 
 
Figure 5(A-C): Characterization of capsule production. (A) capsular concentration/CFU. 
(B) protein concentration/CFU. (C) ratio of supernatant polysaccharide/pellet associated.  
 
Biofilm assay 
          It has been noted that capsule formation in S. pneumoniae inhibits biofilm 
formation (Fielder, et al., 2015). To assess the correlation between GBS capsule and 
biofilm formation, a biofilm formation experiment was performed on all GBS type III 
A B 
C 
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isolates (figure 6). For this assay, O.D. readings were used to assess the amount of 
biofilm formation. O.D. readings were plotted against capsular concentrations for type III 
isolates. Based on the findings with S. pneumoniae, a negative correlation may have been 
expected between GBS capsular concentration and O.D., but, in the case of our GBS type 
III isolates, no correlation was found.  
 
 
Figure 6: Biofilm per capsular concentration.  
 
Type Ia antisera cross reactivity 
The cross reactivity seen between the isolates would impose obstacles in 
identifying purified fractions that contained Ia polysaccharide via a SEC fractions dot 
blot. Initial cross reactivity between isolates may have been attributed to common surface 
proteins that were reacting with the Ia polysaccharide antisera. The experiments checked 
for cross-reactivity between isolates C28, M781, 3 (V), 28 (II), 64 (Ib), and three type Ia 
(20, 21 and 26) using anti-Ia serum. Dot blot performed using type Ia antisera depicted 
cross reactivity between all strains with the exception of M781 (III) and isolate 28 (II) 
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(figure 7 A, left). Type Ia antisera depleted with type V reduced reactivity seen in the 
type V and Ib strains (figure 7A, right).  
To prove the aforementioned point that the GBS antisera was reacting with 
common surface proteins, not just Ia polysaccharide, a Western blot was performed on 
rhizavidin AlpC and Rib (figure 7B). The results showed reactivity towards AlpC for Ib 
antisera, and for both AlpC and Rib for IV antisera. To prove that the antisera was not 
just reacting to the rhizavadin tag, another western was performed with untagged AlpC 
and Rib which revealed similar results (data not shown). 
 
 
Figure 7(A-B): (A) Cross reactivity between type Ia antisera and strains of different GBS 
serotypes. (B) Cross reactivity towards surface proteins AlpC/Rib. 
 
 
HPLC Purification of isolate 26 type Ia and ELISA development 
 
 Broth and supernatants were treated as previously mentioned in the methods 
section. An immunodiffusion assay using isolates 26, 21 and 20 was performed to 
Type	Ia	antisera 
C28								IV	 
M781					III				 
3												V 
28										II 
64										Ib	 
20										Ia 
21										Ia 
26										Ia 
Type	Ia	antisera	
depleted	with	V 
AlpC Rib AlpC Rib 
Ia IV 
50 kd 
A B 
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determine if the capsular polysaccharide of any of these strains would yield a positive 
detection on the gel (antigen-antibody binding). Isolate 26 polysaccharide gave a positive 
detection against the Ia antisera.  
After the positive detection, isolate 26 was grown in 1L of THY for 
polysaccharide purification. After HPLC purification, fractions A7-B14 gave positive 
readings via dot blot with type Ia-TT antisera (figure 8A). By anthrone assay, we found a 
concentration of Ia polysaccharide to be at 125 µg/mL. An inhibition ELISA was 
performed using this HPLC purified capsule (figure 8B). The highest producer of 
polysaccharide was isolate 21.  
 
 
 
  
 
Figure 8(A-B):  (A) Dot blot with anti Ia-TT sera. (B) type Ia ELISA.  
 
 
A9    10         11    12      13      14      15     B1 
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New purification method for GBS type Ia isolate 21   
With the identification of a high producing type Ia isolate, a new polysaccharide 
purification was performed on isolate 21 grown in 2 L THY grown in feed solution. After 
HPLC and anion-exchange purification, a type Ia inhibition ELISA was performed to 
measure polysaccharide concentrations in the fractions and generate an SEC and DEAE 
chromatogram to determine the fractions that contain polysaccharide corresponding to the 
NaCl concentration. From the SEC chromatogram (figure 9, top), the majority of the 
polysaccharide was collected between fractions A10-B14. For the DEAE chromatogram, 
most polysaccharide was collected between A12-A14 (figure 9, bottom).  
 
Figure 9: SEC and DEAE chromatogram. 
 
 An anthrone assay was set up using DEAE fractions A12-B14. We found that the 
average polysaccharide concentration after growth of the organism in a 2 L volume was 
1.1 mg/mL, or 100 µg/mL. 
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AlpC and Rib 
 In order to begin ligation experiments with AlpC, the vector pet 21b was digested 
and ligated with AlpC and Rib (figure 10 A-C).  
 
 
 
Figure 10 (A-C): (A) Digest of pet 21 CRhiz plasmid. (B) Successful ligation of AlpC 
and Rib into Pet21 CRhiz, band size roughly 1 Kb. 
 
To ascertain whether the ligation was successful, the ligated plasmid for AlpC 
was sent for sequencing and aligned with published AlpC sequencing data (figure 11 A-
B). A program called Chromas was used to trim the sequences from the plasmid. Expasy 
was used to translate the DNA to protein, and Clustel Omega was used to align the 
recombinant protein with the published sequence.  
 
MASTIPGSAATLNTSITKNIQNGNAYIDLYDVKLGKIDPLQLIVLEQGFTAKYVFRQGTK 60 
                    
--STIPGSAATLNTSITKNIQNGNAYIDLYDVKLGKIDPLQLIVLEQGFTAKYVFRQGTK 58 
   *********************************************************** 
 
YYGDVSQLQSTGRASLTYNIFGEDGLPHVKTDGQIDIVSVALTIYDSTTLRDKIEEVRTN 120 
YYGDVSQLQSTGRASLTYNIFGEDGLPHVKTDGQIDIVSVALTIYDSTTLRDKIEEVRTN 118 
 ************************************************************ 
      <=AlpC Rhiz => 
ANDPKWTEESRTEVLTGLDTIKTDIDNNPKTQTDIDSKIVEVNELEKLLVLSSMFDASNF 180 
ANDPKWTEESRTEVLTGLDTIKTDIDNNPKTQTDIDSKIVEVNELEKLLVL-SMFDASNF 177 
3 Kb 
A 
1Kb 
B AlpC Rib 
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**************************************************** ********* 
 
KDFSSIASASSSWQNQSGSTMIIQVDSFGNVSGQYVNRAQGTGCQNSPYPLTGRVNGTFI 240 
KDFSSIASASSSWQNQSGSTMIIQVDSFGNVSGQYVNRAQGTGCQNSPYPLTGRVNGTFI 237 
****************************************************************** 
 
AFSVGWNNSTENCNSATGWTGYAQVNGNNTEIVTSWNLAYEGGSGPAIEQGQDTFQYVPT 300 
AFSVGWNNSTENCNSATGWTGYAQVNGNNTEIVTSWNLAYEGGSGPAIEQGQDTFQYVPT 297 
******************************************************************** 
 
TENKSLLKDLEHHHHHH 317 
TENKSLLKD--------  306 
*********         
 
*(signifies matching pair of amino acids) 
 
Figure 11 (A, top, B, bottom): (A) Sequencing of Pet21-CRhizAlpC. Upper sequence 
CRhiz AlpC lower sequence published AlpC and rhizavidin protein sequence. *Indicated 
match amino acids (B) Sequence trace of AlpC term. 
 
After the sequencing data revealed homology between the sequences, the 
recombinant proteins were expressed in T7 shuffle cells and purified via Ni-NTA 
chromatography and visualized by SDS-PAGE (Figure 12A). Fractions containing 
recombinant AlpC were further purified by SEC. Fractions B14-B4 were collected and a 
BCA assay was performed on these fractions. Fractions B7-B10 were pooled giving a 
final protein concentration of 400 µg/mL. After purification, AlpC was sent for 
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immunization studies in rabbits. The immunization titers revealed seroconversion in the 
rabbits to the proteins (figure 12B). AlpC titer was compared to N-terminally tagged as 
well, showing similar titer levels (figure 12C). Additionally, AlpC was complexed to 
pneumococcal type I polysaccharide to form MAPS (figure 12D).  
 
 
 
 
 
 
Alp
C 
A B 
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Figure 12 (A-D): (A) AlpC expression and (B) immunization onto rabbits. (C) Titers of 
AlpC C term vs. N term compared. (D) MAPS construction with AlpC and 
pneumococcal capsule.  
 
 
 
 
 
 
 
 
 
 
 
Boiled 
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DISCUSSION 
 The overarching aim of this thesis was to develop a GBS MAPS vaccine 
comprising of AlpC and Rib coupled to GBS polysaccharides. The underlying hypothesis 
is that this GBS MAPS vaccine will confer serotype-specific immunity via antibodies to 
capsular polysaccharides, and broad range immunity via T cells against GBS proteins.  
To identify high producing capsular Ia and III strains, we first had to serotype 64 
clinical isolates from BCH.  The majority of clinically infectious organisms are type Ia, 
Ib, II, and III, and from these serotypes, Ia, III and V are the most commonly associated 
with EOD (Larsson, et al., 1998; Chaffin, et al., 2000). Based off of these facts, it was 
expected that the majority of the isolates from the 64 would be either type Ia or III. This 
expectation held true, 33% and 54% were type Ia and III, respectively.  
           Once isolates were serotyped, this provided the opportunity to identify isolates that 
were the highest producers of capsule. This was performed via a type 14 pneumococcal 
and Ia inhibition ELISAs. Since type 14 pneumococcal polysaccharide was available and 
cross reacts with type III GBS capsule, this was used as a standard for type III SPC 
measurements. For the type Ia, no polysaccharide was initially available to use as a 
standard. Thus, Ia polysaccharide needed to be purified, but the Ia antisera was cross 
reactive.  
        Such cross-reactivity could complicate the development of a Ia ELISA by 
preventing the identification of which purified fractions contained type Ia 
polysaccharides. It was thought that the cross reactivity seen between isolates was due to 
common cross-reactive surface proteins expressed in different serotypes, such as AlpC 
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and Rib. Other findings have shown that alpha proteins are commonly associated with 
serotypes Ia, Ib and II and these proteins have been shown to cross react with alpha like 
proteins (AlpC) (Areschoug, et al., 1999). As an example of cross reactivity to surface 
proteins, we found cross-reactivity with serotype V in the type Ia dot blot. As it is known 
that type V has alpha-like proteins, our cross reactivity findings between serotype V 
using Ia antisera are consistent with previous results (Lachenauer, et al., 2000). We 
circumvented this cross reactivity problem by treating the supernatants with pronase and 
alkaline to cleave off contaminating proteins, with excellent results. This lead to the 
purification of Ia capsule and allowed for the continuation of the development of a Ia 
ELISA.  
Once the Ia and III ELISAs were developed, the next step was to identify high 
producing strains.  We suspected that some isolates would be producing significantly 
more than others, as some may have enhanced expression of the capsule producing cps 
operon. Another experiment with Group A Strep showed that when a certain regulator for 
capsule synthesis is mutated, the resultant strain has a hyper-invasive phenotype 
(Lynskey, et al., 2013). Therefore, perhaps some of the clinical isolates may have 
differing regulatory systems that hyper-activated capsule production. The results showed 
that indeed isolates differed in capsule production, for example, isolate 25 for the type 
IIIs produced significantly more capsule than M781. Isolate 21 produced the most 
capsule for the Ia.  
After the isolates SPC’s quantification was performed, we next wanted to evaluate 
the effect of growth conditions and media on CPS yield.  In general, shaking conditions 
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contribute to increased aeration and equal mixing of nutrients throughout the media 
(Juergensmeyer, 2007). One study found that in Enterococcus faecalis, shaking 
conditions increased DNA synthesis (Lahti and Heinonen, 1979). Here, we found that 
under shaking conditions, the majority of isolates produced more polysaccharide than 
under static conditions. Similarly, improved growth is observed for most microorganisms 
in rich media. Nutritious media may contain metabolic precursors and thus the organism 
can save metabolic energy by growing in this media (Barbel, et al., 2005). For our 
isolates, the addition of yeast improved the production of CPS. 
Similar to what has been stated before regarding the enhanced expression of the 
cps operon in some isolates, the next experiment looked at if isolate 25 inherently 
produced more capsule than M781, perhaps due to increased expression. This experiment 
showed that isolates 25 and 36 did produce individually more polysaccharide than M781 
according to supernatant readings, instead of reaching to a higher CFU.  
        In all, these previous findings concerning type Ia and III capsule production have 
helped in the purification of polysaccharide to develop MAPS. The next set of 
experiments concerned the carrier proteins for the polysaccharide, AlpC and Rib. As 
previously mentioned, MAPS is dependent on a rhizavadin tag that fuses with biotin on 
the target polysaccharide. Mark Reglinski in this lab was able to express and immunize N 
terminally tagged AlpC. The protein of interest for this thesis was C terminally tagged 
AlpC. One study found that the fusion of the non-immuno-dominant N terminal regions 
of Alpha and Rib proteins elicited a greater immune response than the immuno-dominant 
C-terminal repeats. Therefore, perhaps placing the rhizavadin in the C-terminus and 
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exposing more of the N-terminus would increase anti-AlpC and Rib titers (Carlemalm, et 
al., 2007). If this was the case for AlpC, then generating a C terminally tagged AlpC will 
provide greater protection in MAPS technology. The results did not support previous 
literature. Immunization depicted similar anti-AlpC titers for both forms of the protein. In 
this case, exposing more of the N-terminus did not drastically affect immunity.  
The importance of having AlpC as a carrier protein was exemplified in a study 
performed by Hsia-Hui and co. at Brigham and Women’s Hospital. They reported that 
immunization with the fusion of AlpC with GBS type III polysaccharide rose the IgG 
response from 100 to 64,000. Most importantly, in terms of conferring broad range 
immunity with MAPS, it was depicted that anti-AlpIII titers opsonized strains for GBS 
serotypes V and VIII, in addition to the III (Yang, et al., 2008). Therefore, having two 
purified forms of AlpC (N and C terminally tagged) will contribute to the development of 
a unique GBS MAPS vaccine.  
  
CONCLUSION 
There were five major findings in this thesis. First, we identified the serotype of  
61 of the 64 clinical GBS isolates, and found that 33 of the 64 (54%) were type III. After 
identification, the SPC’s for the type Ia and III isolates were measured via type 14 
pneumococcal and type Ia GBS ELISAs, respectively. Isolate 21 produced the most 
amongst the Ias, and isolate 25 for the IIIs.  A third set of experiments optimized growth 
conditions for the selected type III strains, where it was found that most isolates (25, 32, 
36) produced more SPC in THY than THB, and under shaking rather than static 
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conditions (25, 32, 36, M781). The next group of experiments found that Ia antisera 
reacted to the type IV, Ib and V GBS, and that GBS antisera Ib and IV react with surface 
proteins AlpC and Rib. This finding lead to the development of a method to reduce 
contaminating proteins in the supernatant. Lastly, AlpC was successfully ligated onto the 
pet21-CRhiz plasmid and expressed in T7 shuffle cells. AlpC was complexed to type I 
pneumococcal polysaccharide for the formation of MAPS, and immunization studies with 
this protein depicted similar anti-AlpC titers for C-and N-terminally tagged proteins.  
 The identification of high producing strains for the I and III isolates will help in 
increasing the yield of purified polysaccharide. Future experiments may also identify 
high producing strains for others isolates, followed by polysaccharide purifications. For 
AlpC, the purification will also assist in construction of MAPS with Ia and III 
polysaccharides. It is now known that the placement of the rhizavadin on AlpC does not 
drastically affect immunity, so MAPS development can proceed, for now, without the 
need to place the rhizavadin at a certain location. Future directions with Rib will purify 
the protein and immunize rabbits, and similarly, compare titer levels to N-terminally 
tagged Rib. In all, these experiments have made substantial progress in the development 
of a preclinical GBS MAPS vaccine.  
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